Rigel制药 RIGL 深 沪
等待开盘 10-02 09:30:00 美东时间
28.16
-0.170
-0.60%
华盛通- 最 高28.94
- 今 开28.32
- 成交量 44.90万股
- 最 低 27.9054
- 昨 收 28.33
- 总市值 5.05亿
- 52周最高 43.7181
- 市盈率 静 28.48
- 换手率 2.50%
- 52周最低 13.5705
- 委 比 48.83%
- 总股本 1793.73万
- 历史最高 114.40
- 量 比 0.59
- 振 幅 3.65%
- 历史最低 6.40
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points o...
09-25 02:18
Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
08-06 20:31
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceutical...
07-07 20:05
Rigel Pharmaceuticals Approves Equity Plan Amendment
Rigel ( ($RIGL) ) has issued an announcement. On May 22, 2025, Rigel Pharmaceut...
05-24 04:49
Rigel Pharmaceuticals To Present Final GAVRETO Phase 1/2 ARROW Study Data In RET Fusion-Positive NSCLC And Solid Tumors, Along With Supportive REZLIDHIA Data For mIDH1 R/R AML At ASCO And EHA 2025 Conferences
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with
05-23 05:36
Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
05-07 04:56
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceutica...
04-04 20:05
Rigel settles patent litigation regarding its immune thrombocytopenia treatment
Rigel Pharmaceuticals (RIGL) announced a settlement agreement with Annora Pharma Private, Hetero Labs, and Hetero USA, resolving an ongoing patent dispute related to TAVALISSE, the company's treatment...
03-27 21:59
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Priv...
03-27 20:05
